Guardant Health completed a $550 million private offering of 0% convertible senior notes due 2032. Net proceeds of approximately $538.3 million were used in part to repurchase $395.2 million of its 2027 convertible notes.
GH · Guardant Health, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Close
- $145.59
- Open
- $148.50
- Day range
- $145.40–155.97
- 52-week closing range
- $78.60–187.22
- Average volume, 30 days
- 2.1M
- Short interest
- 9.4M · 7.0% of shares · 5.4 days
- Short volume, last session
- 54%
- Last earnings
- Nov 5, 2026
- Latest filing
- 10-Q · Nov 5
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
Guardant Health raised full-year 2026 revenue guidance to $1.36 to $1.37 billion, after reporting third-quarter revenue of $361.0 million; screening revenue reached $68 million and oncology revenue reached $231 million.
Guardant Health reported revenue of $361.0 million for the three months ended September 30, 2026, up 36% from $265.2 million for the three months ended September 30, 2025. Shield screening revenue rose 180% to $67.6 million.
Guardant Health reported third-quarter revenue of $361.0 million, up 36%, and raised 2026 revenue guidance to $1.36 to $1.37 billion, representing 38% to 40% growth.
Guardant Health expanded its board to 11 by appointing Kevin R. Sayer effective November 2, 2026, and appointed Robert A. Parks Chief Accounting Officer. Sayer will receive a $500,000 restricted stock unit award and a $60,000 per year cash retainer.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 5, 2026TL;DR. Third-quarter revenue grew 36%, full-year revenue and screening guidance were raised, oncology-volume guidance increased to more than 50%, non-GAAP gross-margin guidance increased to 65%, SHIELD costs and coverage improved, and Guardant360 CDx received an additional major approval. GAAP net loss and operating expenses increased, full-year operating-expense and free-cash-flow burn guidance worsened, and management expects Shield ASP to tick down.
- + SHIELD cost per test fell from $410 in Q2 to $330 in Q3, surpassing the $350 year-end target a quarter early. new
- + Expanded SHIELD coverage is expected to provide access for approximately 100 million people, representing more than 80% of the eligible U.S. screening population in 2027. new
- + Guardant360 CDx received FDA approval for ETCAMAH and CE marking in Europe. new
- + Full-year non-GAAP gross-margin guidance increased to 65%. new
- − GAAP net loss increased to $124.4 million from $92.7 million. new
- − Full-year free-cash-flow burn guidance increased to $205 million-$220 million from $195 million-$205 million.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -152.07M | Nine Months Ended September 30, 2026 | — |
| Adjusted EBITDA loss non-GAAP | $37.3M | the third quarter of 2026 | — |
|
|
|||
| Free cash flow non-GAAP | -177.93M | Nine Months Ended September 30, 2026 | — |
|
|
|||
| Non-GAAP gross margin non-GAAP | 67% | the third quarter of 2026 | — |
|
|
|||
| Non-GAAP loss from operations non-GAAP | -180.32M | Nine Months Ended September 30, 2026 | — |
| Non-GAAP net loss non-GAAP | -153.66M | Nine Months Ended September 30, 2026 | — |
| Non-GAAP net loss per share non-GAAP | $0.29 | the third quarter of 2026 | — |
|
|
|||
| Non-GAAP net loss per share, basic and diluted non-GAAP | -$1.16 | Nine Months Ended September 30, 2026 | — |
| Non-GAAP operating expenses non-GAAP | $287.4M | the third quarter of 2026 | — |
|
|
|||
| Oncology tests | 117,000 | the third quarter of 2026 | — |
|
|
|||
| Shield tests | 83,000 | the third quarter of 2026 | — |
| Shield screening test volume | 66,000 | the three months ended June 30, 2026 filing | — |
| Shield screening tests | 66,000 | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GH
this stock
Guardant Health, Inc.
|
$19.70B | +42.5% | +32.9% | — | 7.0% |
|
TMO
Thermo Fisher Scientific Inc.
|
$255.19B | +18.9% | +14.5% | 36.3 | 1.3% |
|
DHR
Danaher Corp
|
$160.10B | -0.6% | +8.5% | 37.2 | 1.2% |
|
IDXX
Idexx Laboratories Inc
|
$54.33B | +1.9% | +10.4% | 46.5 | 3.0% |
|
A
Agilent Technologies, Inc.
|
$49.43B | +28.9% | +6.4% | 34.5 | 1.7% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 16, 2026
- This year
- 25
Guardant Health completed a $550 million private offering of 0% convertible senior notes due 2032. Net proceeds of approximately $538.3 million were used in part to repurchase $395.2 million of its 2027 convertible notes.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GH | -6.0% | -10.7% | +12.7% | -18.6% | +42.5% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | -0.5% | -4.4% | +18.4% | -13.3% | +37.6% |